Levofloxacin Causes QTc Prolongation; Trimethoprim-Sulfamethoxazole Does Not
Levofloxacin (a fluoroquinolone) definitively causes QTc interval prolongation, while trimethoprim-sulfamethoxazole (TMP-SMX) does not prolong the QTc interval. When choosing between these antibiotics for susceptible infections, TMP-SMX is the safer option from a cardiac standpoint, particularly in patients with existing QTc prolongation risk factors.
Evidence for Levofloxacin's QTc Prolongation Risk
The FDA drug label for levofloxacin explicitly warns that "some fluoroquinolones, including levofloxacin, have been associated with prolongation of the QT interval on the electrocardiogram and infrequent cases of arrhythmia. Rare cases of torsade de pointes have been spontaneously reported during postmarketing surveillance" 1. The label specifically states that levofloxacin should be avoided in patients with known QT prolongation, uncorrected hypokalemia, and those receiving Class IA or Class III antiarrhythmic agents 1.
Current guidelines from the 2023 Canadian Cardiovascular Society confirm that among fluoroquinolone antibiotics, none are safe regarding QTc prolongation 2. The guidelines explicitly list fluoroquinolones among the "anti's" that commonly cause acquired long QT syndrome (aLQTS), alongside macrolides, antifungals, antiarrhythmics, and antipsychotics 2.
Clinical Evidence Quantifying the Risk
Research demonstrates measurable QTc prolongation with levofloxacin:
- In cardiac patients with pneumonia, over 80% experienced QTc prolongation after levofloxacin administration, with a mean increase of 15.68 ± 26.84 milliseconds 3
- A comparative study showed levofloxacin had 4 times greater relative risk for QTc prolongation than ciprofloxacin in diabetic patients and 1.5 times greater risk in non-diabetic patients 4
- Among hematopoietic cell transplant recipients receiving levofloxacin with triazoles, 22% developed QTc prolongation 5
TMP-SMX as the Safer Alternative
Trimethoprim-sulfamethoxazole is not listed among QTc-prolonging antibiotics in any guideline or drug safety resource. The 2023 Canadian guidelines specifically recommend penicillins and cephalosporins as safe alternatives to fluoroquinolones when QTc prolongation is a concern 2. TMP-SMX falls into this category of antibiotics without significant cardiac conduction effects.
When treating Stenotrophomonas maltophilia infections—where both agents are options—a large multicenter study found no difference in mortality or clinical outcomes between TMP-SMX and levofloxacin, but TMP-SMX avoided the cardiac risk 6.
Clinical Decision Algorithm
When both antibiotics are microbiologically appropriate:
Use TMP-SMX preferentially in patients with:
If levofloxacin must be used, obtain:
Avoid levofloxacin entirely when:
- Patient already taking Class IA or III antiarrhythmics 1
- Congenital long QT syndrome present
- Recent cardiac arrest or acute coronary syndrome
Critical Risk Threshold
The risk for torsades de pointes increases significantly when QTc exceeds 500 ms or when a drug increases QTc by >60-70 ms, particularly when this increase develops rapidly 2. This threshold should trigger immediate drug discontinuation.
Common Pitfall to Avoid
Do not assume all fluoroquinolones carry equal risk—while the 2023 guidelines state "none are safe," there are gradations. However, this distinction is irrelevant when comparing to TMP-SMX, which carries no QTc risk. The key error is continuing levofloxacin when TMP-SMX would be equally effective microbiologically, simply out of prescribing habit.